Work

FDA report to Congress on advisory committee conflicts of interest, FY 2023

The FDA's annual report on advisory committee vacancies, waivers and conflicts of interest.

1 link, 1 backed by primary records

Connections 1

Timeline 1 date

2023 FDA report to Congress on advisory committee conflicts of interest, FY 2023

Proof 1 source

Report to Congress: Fiscal Year 2023 Advisory Committee Vacancies and Conflicts of Interest, U.S. Food and Drug Administration. Primary record
FDA granted 23 waivers under 18 U.S.C. 208(b)(3) in FY 2023 (less than 3 percent of total meeting participants in attendance at meetings)
if the need for the individual's services outweighs the potential for a conflict of interest created by the financial interest involved.
This information is posted on FDA’s website prior to each meeting.

Page history 1 change